Y-mabs Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy YMAB

*Your capital is at risk

$8.61

+0 (+0%)

At Close: Dec 15, 2025

Currently predicting for Thu, 6 Aug 2026

YMAB Live board

Community Bull/Bear

Target Next close

Join the YMAB prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

YMAB Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For YMAB

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

YMAB Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT Y-MABS THERAPEUTICS INC.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
N NXDR $2.27	7.93%	Aug 03
MC $67.08	3.53%	Jul 31
FCX $62.63	10.79%	Jul 31
ARW $212.85	6.58%	Jul 30
BIIB $202.19	2.20%	Jul 24

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by